Cellectar Provides Update on Phase 1 Trial of CLR 131 in Relapsed/Refractory Multiple Myeloma
January 07, 2019 08:30 ET
|
Cellectar Biosciences, Inc.
FLORHAM PARK, N.J., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Cellectar Biosciences to Present at the Biotech Showcase
January 03, 2019 08:30 ET
|
Cellectar Biosciences, Inc.
FLORHAM PARK, N.J., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Cellectar Granted Japanese Patent for CLR 131
December 11, 2018 08:30 ET
|
Cellectar Biosciences, Inc.
FLORHAM PARK, N.J., Dec. 11, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and...
Cellectar Initiates Cohort 6 of Phase 1b Trial Evaluating CLR 131 in Relapsed/Refractory Multiple Myeloma
December 04, 2018 08:30 ET
|
Cellectar Biosciences, Inc.
FLORHAM PARK, N.J., Dec. 04, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Cellectar Reports Third Quarter 2018 Financial Results and Provides Business Update
November 13, 2018 08:30 ET
|
Cellectar Biosciences, Inc.
FLORHAM PARK, N.J., Nov. 13, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (“Cellectar” or “the Company”), a clinical-stage biopharmaceutical company focused on the discovery,...
Cellectar Announces FDA Grants Exemption to Import Alert for CLR 131 Hematology Studies
November 12, 2018 08:30 ET
|
Cellectar Biosciences, Inc.
Clinical Trials to Advance Across Multiple Hematology Programs FLORHAM PARK, N.J., Nov. 12, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical...
Cellectar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma
October 02, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Oct. 02, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs...
Cellectar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference
September 27, 2018 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Sept. 27, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
Cellectar’s CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma
September 25, 2018 08:30 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Sept. 25, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...
Cellectar Biosciences Provides an Update on the FDA Import Alert
September 24, 2018 08:00 ET
|
Cellectar Biosciences, Inc.
MADISON, Wis., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization...